Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 29 April 2016 -...
-
If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Press Release Geneva, 29 April 2016 ...
-
Ci Com RESULTATS ANNUELS 2015 Genève, le 28 Avril 2016 Faits Marquants Participations financières 8 070 KCHF Résultat net consolidé (100% part du groupe) - 424 KCHF Cours du 27/04/16 4,47 CHF...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} 28 April 2016 -...
-
First quarter 2016 sales from continuing operations increased 3 % in local currencies to CHF 1.478 billion EBITDA margin before exceptional items improved to 15.5 % from...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} 28 April 2016, Road Town, Tortola, BVI As of 31...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Dividendenausschüttung von CHF 0.65 pro...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Dividend of CHF 0.65 per share out...
-
Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential...